June is always a crazy busy month in the conference calendar, and as usual, the ASCO Annual Meeting and the EHA Annual Congress were a hub of activity, data and discussion. We interviewed several experts on the latest news in multiple myeloma (MM) and have summarized the most exciting updates below.
POLLUX clinical trial: the best triplet combination so far in MM
The Phase III POLLUX clinical trial of daratumumab with lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed/refractory patients, was reported at EHA 2016. Daratumumab is an anti-CD38 monoclonal antibody, which is currently approved in the US for patients with relapsed/refractory MM. 
The overall response rate (ORR) was 93% in the DRd arm vs 76% in the Rd arm. The addition of daratumumab also increased the very good partial response (VGPR) and complete remission (CR) rates (76% vs 44% and 43% vs 19%, respectively). Further, the median progression-free survival (PFS) was improved in patients receiving the triplet combination, with a 63% reduction in the risk of progression, compared with those who did not receive daratumumab. 
According to Dr Niels van de Donk, “this is the best triplet combination tested so far”. In a video summarizing the results from the POLLUX trial (see below), he also discusses the MAIA clinical trial, which will look at daratumumab in the upfront setting.
CASTOR clinical trial: a new paradigm for treatment
The Phase III CASTOR clinical trial was presented at ASCO 2016 and looked at the combination of daratumumab with bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) alone in relapsed/refractory MM patients.
The addition of daratumumab increased the ORR, which was 83% in the DVd vs 63% in the Vd arm, and further improved PFS, with a 61% reduction in risk of progression. The rates of VGPR and CR doubled (59% vs 29% and 19% vs 9% respectively). 
“This trial had to be stopped early because of the overwhelming superiority of the triplet combination,” Prof. Keith Stewart from the Mayo Clinic points out in a video summarizing the two trials.
According Dr Antonio Palumbo from the University of Turin, who presented the results at ASCO, daratumumab will “change the treatment paradigm”. In future, daratumumab will be added to either the bortezomib and dexamethasone or the lenalidomide and dexamethasone backbone.
Prof. Philippe Moreau from the University Hospital of Nantes also points out that, down the line, daratumumab may also be used for patients with one or two prior lines of treatment, and patients who are not eligible for stem cell transplantation.
Dr Palumbo explains the results and daratumumab’s mode of action below.
Will FISH become obsolete?
“Arguably, FISH is dead,” according to Prof. Gareth Morgan of the UAMS Myeloma Institute.
Fluorescence in situ hybridization, better known as FISH, is a test used to map and visualize genetic material. FISH can be used to detect genetic abnormalities, which is crucial in MM, as more subtypes are being identified. FISH can then be a helpful tool for physicians when selecting the most appropriate treatment, allowing for a personalized approach.
As we move towards precision medicine, “we need tools that identify these groups [of patients]”, as Prof. Gareth Morgan points out. However, FISH is slow, prone to error and expensive. Prof. Morgan argues that in light of next-generation sequencing (NGS), FISH will become obsolete.
The topic of FISH was previously reviewed by Prof. Chng Wee Joo, Prof. Morgan and Prof. Michele Cavo, during a panel discussion on the status of genomics at Myeloma 2016. Experts agree that FISH will be abandoned in favor of NGS in the near future.
If you would like to discover how we can leverage our network of relationships and understanding of the haematological oncology landscape and stakeholders, to shape content and amplify messages across relevant audiences, channels and communities please contact Stephen Dunn or Charlie Grieve on 020 7291 5070, we’d be delighted to hear from you.